Biosimilar commercialization company
Appears in 1 story
Holds exclusive US commercialization rights to Lucamzi
After four years and two FDA rejections, Xbrane Biopharma has US approval for its copy of Lucentis, one of the world's best-selling eye drugs. The regulator cleared Lucamzi (ranibizumab-blrz) two days before its own October 29 review deadline.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
